News
Topics
PRD Therapeutics Initiates First-in-Human Clinical Trial of SOAT2-Selective Inhibitor ‘PRD001’ — Axcelead DDP Provides Comprehensive Non-Clinical Development Support —
PRD Therapeutics, Inc. (“PRD Therapeutics”), a clinical stage company focused on developing novel lipid metabolism regulators targeting homozygous...
Researcher Oki from Screening BU to Deliver an Oral Presentation at the 52nd Annual Workshop of the Japanese Society of Toxicology
Our researcher, Hideyuki Oki from the Screening Business Unit, will deliver an oral presentation at the 52nd...
Researcher Hamada from DMPK BU to Present a Poster at the 52nd Annual Meeting of the Japanese Society of Toxicology
Our researcher, Teruki Hamada from the DMPK Business Unit, will present a poster at the 52nd Annual...
Dr. Fukui (Senior Director, Safety BU) to Deliver an Oral Presentation at the 52nd Annual Workshop of the Japanese Society of Toxicology
Senior Director and Senior Consultant Dr. Fukui from the Safety Business Unit will deliver an oral presentation...
Researcher Yoshida from Safety BU to Present a Poster at the 10th Annual Meeting of the Japan Nucleic Acid Therapeutics Society
Our researcher, Ikuma Yoshida from the Safety Business Unit, will present a poster at the 10th Annual...